Lexicon Pharmaceuticals Q3 EPS $(0.03) Beats $(0.06) Estimate, Sales $11.250M Beat $4.142M Estimate
Benzinga Newsdesk 11 hours ago
NewsEarningsEarnings Beats
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 25 percent increase over losses of $(0.04) per share
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $11.250 million which beat the analyst consensus estimate of $4.142 million by 171.61 percent. This is a 20.67 percent decrease over sales of $14.182 million the same period last year.